Literature DB >> 2149648

Self- and observer assessment in anxiolytic drug trials: a comparison of their validity.

W Maier1, M Albus, R Buller, D Nutzinger, D Shera, P Bech.   

Abstract

Self-rating scales are considered to be less useful for comparing different treatments in anxiety patients than observer-rating scales. However, the empirical evidence for this assumption is not adequate. A self-rating inventory of 35 items related to anxiety was perfectly parallel with an observer-rating inventory. Both instruments were used in the Cross National Collaborative Panic Study to compare the efficacy of imipramine, alprazolam and placebo in an 8-week drug trial in a sample of 1168 outpatients. The variance of the self-rating assessments was about two times higher. Both scales were equally sensitive to change; however, the measurement of change by means of the self-rating scale was slightly less consistent. The discriminative power of the observer-rating scale between placebo and active treatment was two to three times higher than that of the self-rating scale; consequently the observer-rating procedure provides a more valid instrument when the efficacies of different anxiolytic treatments are compared between different groups of patients.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2149648     DOI: 10.1007/bf02189979

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  9 in total

1.  Drug treatment of panic disorder. Comparative efficacy of alprazolam, imipramine, and placebo. Cross-National Collaborative Panic Study, Second Phase Investigators.

Authors: 
Journal:  Br J Psychiatry       Date:  1992-02       Impact factor: 9.319

2.  Consistencies and discrepancies in self- and observer-rated anxiety scales. A comparison between the self- and observer-rated Marks-Sheehan scales.

Authors:  M Albus; W Maier; D Shera; P Bech
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1990       Impact factor: 5.270

Review 3.  Antidepressants in panic disorder and agoraphobia.

Authors:  R B Lydiard; J C Ballenger
Journal:  J Affect Disord       Date:  1987 Sep-Oct       Impact factor: 4.839

4.  SCL-90: an outpatient psychiatric rating scale--preliminary report.

Authors:  L R Derogatis; R S Lipman; L Covi
Journal:  Psychopharmacol Bull       Date:  1973-01

5.  Brief standard self-rating for phobic patients.

Authors:  I M Marks; A M Mathews
Journal:  Behav Res Ther       Date:  1979

6.  Overview of the Cross-National Collaborative Panic Study.

Authors:  G L Klerman
Journal:  Arch Gen Psychiatry       Date:  1988-05

7.  Meta-analysis and the evaluation of psychotherapy outcome: limitations and liabilities.

Authors:  G T Wilson; S J Rachman
Journal:  J Consult Clin Psychol       Date:  1983-02

8.  The value of self-report assessment in studies of anxiety disorders.

Authors:  R M Glass; E H Uhlenhuth; R Kellner
Journal:  J Clin Psychopharmacol       Date:  1987-08       Impact factor: 3.153

9.  Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment.

Authors:  J C Ballenger; G D Burrows; R L DuPont; I M Lesser; R Noyes; J C Pecknold; A Rifkin; R P Swinson
Journal:  Arch Gen Psychiatry       Date:  1988-05
  9 in total
  2 in total

1.  Consistencies and discrepancies in self- and observer-rated anxiety scales. A comparison between the self- and observer-rated Marks-Sheehan scales.

Authors:  M Albus; W Maier; D Shera; P Bech
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1990       Impact factor: 5.270

Review 2.  Antidepressants versus placebo for panic disorder in adults.

Authors:  Irene Bighelli; Mariasole Castellazzi; Andrea Cipriani; Francesca Girlanda; Giuseppe Guaiana; Markus Koesters; Giulia Turrini; Toshi A Furukawa; Corrado Barbui
Journal:  Cochrane Database Syst Rev       Date:  2018-04-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.